Susquehanna Fundamental Investments LLC Makes New Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

Susquehanna Fundamental Investments LLC purchased a new position in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 291,383 shares of the company's stock, valued at approximately $1,643,000. Susquehanna Fundamental Investments LLC owned 0.34% of Verve Therapeutics at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VERV. Geode Capital Management LLC raised its stake in shares of Verve Therapeutics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,600,687 shares of the company's stock worth $7,749,000 after buying an additional 40,915 shares during the last quarter. Barclays PLC raised its position in Verve Therapeutics by 139.8% during the third quarter. Barclays PLC now owns 222,919 shares of the company's stock worth $1,079,000 after acquiring an additional 129,944 shares during the last quarter. Franklin Resources Inc. lifted its holdings in shares of Verve Therapeutics by 20.9% in the third quarter. Franklin Resources Inc. now owns 34,155 shares of the company's stock valued at $172,000 after purchasing an additional 5,914 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after purchasing an additional 3,964 shares during the last quarter. Finally, Green Alpha Advisors LLC increased its stake in shares of Verve Therapeutics by 15.0% during the 4th quarter. Green Alpha Advisors LLC now owns 29,438 shares of the company's stock worth $166,000 after purchasing an additional 3,840 shares in the last quarter. 97.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on VERV. Canaccord Genuity Group increased their target price on Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. HC Wainwright lifted their price objective on Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research report on Monday, April 14th. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, April 15th. Guggenheim lifted their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Finally, Royal Bank of Canada cut their price objective on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a research report on Tuesday, March 4th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $25.75.

Verve Therapeutics Trading Down 1.1 %

Shares of NASDAQ VERV traded down $0.06 on Monday, reaching $5.14. 1,340,410 shares of the company traded hands, compared to its average volume of 2,474,110. The company has a 50 day moving average of $5.16 and a 200 day moving average of $5.96. Verve Therapeutics, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $9.31. The stock has a market capitalization of $457.75 million, a PE ratio of -2.09 and a beta of 1.86.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The company had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. As a group, research analysts expect that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.